37 results on '"anti-VEGF"'
Search Results
2. Venöse retinale Gefäßverschlüsse: Intravitreale Therapien und Strategien zur Behandlung des Makulaödems.
- Author
-
Hattenbach, Lars-Olof, Chronopoulos, Argyrios, and Feltgen, Nicolas
- Abstract
Copyright of Die Ophthalmologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
3. Epidemiologie und Therapie der behandlungsbedürftigen Frühgeborenenretinopathie. Die Hannoveraner Daten im Retina.net ROP-Register von 2001 bis 2017.
- Author
-
Akman, Stella H., Pfeil, Johanna M., Stahl, Andreas, Ehlers, Stephanie, Böhne, Carolin, Bohnhorst, Bettina, Framme, Carsten, Brockmann, Dorothee, Bajor, Anna, Jacobsen, Christina, Hufendiek, Karsten, Pielen, Amelie, Retina.net ROP Register-Studiengruppe, Behrens, Julia, Luger, Benjamin, Mies, Sophia, Wojtera, Nora, and Zirkler, Carina
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
4. Das modifizierte Treat-and-Extend-Schema mit Injektionsblöcken in der IVOM-Therapie: Retrospektive Analyse aus der täglichen klinischen Anwendung.
- Author
-
Take, Patricia, Dittmann, Carolin Alisa, Mackerodt, Laura, Callizo, Josep, Striebe, Nina-Antonia, Hoerauf, Hans, Feltgen, Nicolas, and Bemme, Sebastian
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
5. Diagnostische Kriterien: OCT‑Angiographie bei retinalen angiomatösen Proliferationen (RAP‑Läsionen, Typ‑3-Neovaskularisationen).
- Author
-
Valler, D., Feucht, N., Lohmann, C. P., Ulbig, M., and Maier, M.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
6. Trabekulektomie mit Ologen®-Implantat und Bevacizumab.
- Author
-
Glandorf, K., Lommatzsch, C., Heinz, C., and Koch, J. M.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
7. [Vitreous body in the treatment of exudative age-related macular degeneration : The medium is the message].
- Author
-
Schultheiss M, Haritoglou C, Boneva S, Binder S, and Sebag J
- Subjects
- Humans, Vitreous Body, Vascular Endothelial Growth Factor A therapeutic use, Vitreous Detachment, Retinal Diseases, Macular Degeneration drug therapy
- Abstract
Background: Intravitreal anti-vascular endothelial growth factor (VEGF) is the standard treatment for exudative age-related macular degeneration (AMD). The constitution of the vitreomacular interface varies greatly in cases of attached (with or without traction) or detached vitreous body, which can impact the effectiveness of the anti-VEGF treatment., Objective: Based on the current literature this article displays the current state of the science on whether the constitution of the vitreous body has an effect on the anti-VEGF treatment., Material and Methods: The published data extracted from current trials and post hoc analyses concerning this topic are presented and put into the clinical context., Results: The presence of a vitreomacular adhesion reduces the efficacy of anti-VEGF treatment of exudative AMD. Posterior vitreous body detachment represents a positive prognostic factor concerning the efficacy of anti-VEGF treatment but not necessarily the prognosis for visual acuity., Conclusion: Patients with attached vitreous body need a more intensive treatment monitoring compared to patients with detached vitreous body. Therefore, in eyes with initial posterior vitreous body detachment receiving a treat and extend regimen, the interval between anti-VEGF injections can be extended to 4 instead of 2 weeks without endangering the success of treatment., (© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
8. Behandlungsrealität mit Ranibizumab in der klinischen Routineanwendung bei Patienten mit diabetischem Makulaödem: 1-Jahres-Ergebnisse der deutschen POLARIS-Kohorte.
- Author
-
Ulbig, M., Höh, H., Schmickler, S., Wolf, A., Dimopoulos, S., Lorenz, K., Bauer-Steinhusen, U., and Wiedemann, P.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
9. Gründe für Therapieverzögerung und -abbruch bei altersabhängiger Makuladegeneration.
- Author
-
Wintergerst, M. W. M., Bouws, J., Loss, J., Heimes, B., Pauleikhoff, D., Holz, F. G., and Finger, R. P.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
10. Zentralvenenverschluss bei Wyburn-Mason-Syndrom.
- Author
-
Toepffer, Anne-Marie, Wecke, Thoralf, Hoffmann, Michael B., and Thieme, Hagen
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
11. Volumetrische Analyse der vaskularisierten Pigmentepithelabhebung bei AMD: Post-hoc-Analyse der RECOVER-Studie.
- Author
-
Clemens, C. R., Alten, F., Heiduschka, P., Gamulescu, M. A., Wolf, A., and Eter, N.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
12. Behandelte Frühgeborenenretinopathie in Deutschland.
- Author
-
Walz, J. M., Bemme, S., Reichl, S., Akman, S., Breuß, H., Süsskind, D., Glitz, B., Müller, V. C., Wagenfeld, L., Gabel-Pfisterer, A., Aisenbrey, S., Engelmann, K., Koutsonas, A., Krohne, T. U., Stahl, A., and Retina.net ROP-Register-Studiengruppe
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
13. Neu aufgetretene Visusminderung bei choroidalem Osteom.
- Author
-
Schuh, A., Foerster, P., Priglinger, S., and Eibl-Lindner, K.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
14. Stellenwert der Vitrektomie bei Endophthalmitis: Wie eine prompte Vitrektomie den Visus wiederherstellen kann.
- Author
-
Damm, L.‑J., Boden, K. T., and Januschowski, K.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
15. Design des ORCA-Moduls der OCEAN-Studie.
- Author
-
Heimes, B., Schick, T., Brinkmann, C.K., Wiedon, A., Haegele, B., Kirchhof, B., Holz, F.G., Pauleikhoff, D., Ziemssen, F., Liakopoulos, S., Spital, G., and Schmitz-Valckenberg, S.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
16. Die Häufigkeit von submakulären Blutungen bei altersabhängiger Makuladegeneration bei unterschiedlichen Therapieformen.
- Author
-
Großpötzl, Manuel, Seidel, Gerald, Rabensteiner, Dieter, and Haas, Anton
- Abstract
Copyright of Spektrum der Augenheilkunde is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
- Full Text
- View/download PDF
17. [Retinal vein occlusion : Intravitreal pharmacotherapies and treatment strategies for the management of macular edema].
- Author
-
Hattenbach LO, Chronopoulos A, and Feltgen N
- Subjects
- Humans, Vascular Endothelial Growth Factor A therapeutic use, Bevacizumab therapeutic use, Intravitreal Injections, Retinal Vein Occlusion complications, Macular Edema drug therapy
- Abstract
Intravitreal injection treatment for the management of macular edema as an expression of increased capillary permeability and leakage constitute the mainstay of treatment in retinal vein occlusion. In contrast to diabetic retinopathy or neovascular age-related macular degeneration, permanent and complete functional and morphological restoration can be achieved, as retinal vein occlusions are usually associated with risk factors, but do not represent the manifestation form of an underlying systemic or degenerative chronic disorder; however, successful long-term management of retinal vein occlusion -associated macular edema usually requires intensive and also long-term continued treatment with vascular endothelial growth factor (VEGF) inhibitors or with a less favorable side effect profile, dexamethasone. A functional treatment success can be maintained over the long term by both pro re nata (PRN) or treat and extend (T&E) regimens. In contrast, according to the currently available data, the combination of anti-VEGF administration and grid laser treatment has no additional benefit compared to monotherapy. In patients with recalcitrant macular edema, switching to another intravitreal agent may be considered during the course of treatment, although a true therapeutic benefit with respect to the development of visual acuity has not yet been proven. The current review summarizes the relevant aspects in the management of RVO-associated macular edema and provides the foundations for the application of successful treatment strategies., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
18. Digitale Weitwinkelfotographie in der Untersuchung von Frühgeborenenretinopathie: 6-Jahres-Ergebnisse einer deutschen Universitäts-Augenklinik
- Author
-
Parlak, Melih, Lang, Gabriele E., and Weiß, Manfred
- Subjects
Frühgeborenenretinopathie ,Retrolentale Fibroplasie ,Retinale Bildgebung ,Retinopathy of prematurity ,Digitaltechnik ,anti-VEGF ,Retinal diseases ,Diagnosis ,Frühgeborenes ,ddc:610 ,Weitwinkelfotografie ,DDC 610 / Medicine & health ,Infant, Premature ,Retinopathie - Abstract
Die Retinopathia praematurorum (ROP) ist eine retinale Gefäßerkrankung, die zu den wichtigsten kindlichen Erblindungsursachen zählt. Sie stellt eine Komplikation der Unreife dar und steht im Zusammenhang mit postnataler Sauerstoffgabe. Für die Prävention von ROP assoziierter Erblindung ist eine genaue Diagnostik und effiziente Therapie entscheidend. Hierfür wurden Screening-Programme etabliert um progressive Krankheitsbilder, die ohne Behandlung zu einer Netzhautablösung fortschreiten können, rechtzeitig zu erkennen. Die herkömmliche ROP Untersuchung mit indirekter Ophthalmoskopie ist bei unreifen Augen mit trüben brechenden Medien eine anspruchsvolle Untersuchungstechnik. Subjektiv ermittelte Befunde werden anhand von Skizzen dokumentiert. Hiermit ist eine genaue Progressionsanalyse nur bedingt möglich. In dieser Hinsicht sind objektive Untersuchungsergebnisse wünschenswert, wo wiederum die digitale Weitwinkelfotographie der Netzhaut zunehmend an Bedeutung gewinnt. Die Studie untersucht die unizentrischen ROP Screening Ergebnisse mit digitaler Weitwinkelfotographie in einem Zeitraum von 6 Jahren. Anhand von objektiven Bilddaten wurden die ROP-Charakteristika, Zusammenhang zu Komorbiditäten, Therapieergebnisse und die Effizienz des Screening-Programms analysiert. Zu diesem Zweck wurden Bilddaten und Patientenakten von 540 Frühgeborenen, die das komplette Screening-Programm durchlaufen haben, untersucht. Das durchschnittliche Gestationsalter betrug 28,3 Wochen und das mittlere Geburtsgewicht 1173 Gramm. Bei der ordinal logistischen Regressionsanalyse war das Gestationsalter und Geburtsgewicht über alle ROP Parameter hinweg der wichtigste Prädiktor für eine ROP. Alle untersuchten Komorbiditäten waren im multivariablen Modell nicht statistisch signifikant. Über den Studienzeitraum wurden bei den 540 Frühgeborenen insgesamt 2273 Netzhautuntersuchungen durchgeführt. Hiervon wurden insgesamt 79.166 Netzhautbilder analysiert. In Bezug auf die Untersuchungs- und Bildanzahl wurde kein zeitlicher Trend festgestellt.In der Studienkohorte wurde bei 238 von 540 Säuglingen (44%) eine ROP festgestellt. Zwischen beiden Augen lag eine sehr hohe Symmetrie vor. Über die gesamte Studienlaufzeit war das häufigste Krankheitsstadium eine prominente Leiste (Stadium 2) bei 43%, gefolgt von Stadium 1 (29,8%), Stadium 3 (26,4%), Stadium 4 (0,8%), und Stadium 5 (0,4%). Zwischen 2013 und 2018 wurden 33 Kinder aufgrund einer ROP behandelt. Der Anteil an behandlungsbedürftiger ROP zeigte starke Variationen über den Studienzeitraum. Die am häufigsten durchgeführte Behandlungstechnik war die retinale Laserfotokoagulation (28 Kinder, 85%). Bei 3 Kindern wurde eine intravitreale anti-VEGF-Therapie (vascular endothelial growth factor) (9%) durchgeführt. Die digitale Weitwinkelfotographie der Netzhaut stellt eine zuverlässige Untersuchungstechnik für die ROP Untersuchung dar. Sie ersetzt die indirekte Ophthalmoskopie nicht, ergänzt sie aber mit bedeutenden Vorteilen. Sie ermöglicht eine genaue Progressionsanalyse und bei kritischen Fällen eine Fernkonsultation. Zudem hat sie ein großes Potential in der ophthalmologischen und speziell kinderretinologischen Ausbildung. Im Hinblick auf die technologischen Fortschritte wird sie voraussichtlich weiterentwickelt und mit anderen Diagnoseprogrammen erweitert. Insbesondere Zukunftstechnologien, die künstliche Intelligenz und maschinelles Lernen einsetzen, könnten wichtige diagnostische Hilfestellungen leisten. Wenn erforderliche Voraussetzungen erfüllt sind, könnte hiermit auch in der Zukunft ein kompetentes telemedizinisches Behandlungskonzept flächendeckend angewendet werden.
- Published
- 2020
- Full Text
- View/download PDF
19. [Epidemiology and treatment of retinopathy of prematurity. The Hannover data in the Retina.net ROP registry from 2001-2017].
- Author
-
Akman SH, Pfeil JM, Stahl A, Ehlers S, Böhne C, Bohnhorst B, Framme C, Brockmann D, Bajor A, Jacobsen C, Hufendiek K, and Pielen A
- Subjects
- Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Female, Gestational Age, Humans, Infant, Infant, Newborn, Infant, Premature, Intravitreal Injections, Laser Coagulation, Male, Registries, Retina, Retrospective Studies, Vascular Endothelial Growth Factor A, Retinopathy of Prematurity diagnosis, Retinopathy of Prematurity epidemiology, Retinopathy of Prematurity therapy
- Abstract
Background: The Retina.net ROP registry documents data of preterm infants developing stages of retinopathy of prematurity (ROP) that need ROP treatment. The aim of this analysis was to investigate data regarding epidemiology, therapy and changes over time (15 years) in a single participating center (Hannover Medical School, MHH)., Methods: Analysis of data of infants treated for ROP at a single center over time (birth 2001-2016, ROP treatment in 2002-2017)., Results: Overall, 65 infants were treated (23 female). In 11 infants (16.9%) ROP screening was conducted externally and infants were transferred to the MHH for ROP treatment. Between 2006 and 2016, incidence of ROP requiring treatment among infants screened for the development of ROP was 4.1%. Mean gestational age was 25.7 weeks (standard deviation, SD 1.8), mean birth weight 763 g (SD 235), postmenstrual age at treatment 38.2 weeks (SD 3.2), postnatal age 12.4 weeks (SD 3.2). There was no significant change in parameters over time. ROP zone II, stage 3+ was most frequently treated (57 eyes of 31 infants). 58 infants were treated with laser (114 eyes), 7 infants were treated with anti-VEGF (bevacizumab, bilateral, 14 eyes) from 2014 onwards. Retreatment due to recurrence of ROP was necessary in one infant after initial laser coagulation. Infants with ROP requiring treatment often presented with neonatal comorbidities, ventilation in more than 90%, bronchopulmonary dysplasia, and received transfusions., Conclusion: This is the first monocentric analysis over 15 years originating from the Retina.net ROP registry. In this cohort we see a change in ROP therapy from laser coagulation to anti-VEGF (bevacizumab) from 2014 onwards, demographic data and treatment parameters remained relatively stable over time., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
20. Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auge.
- Author
-
Kernt, M., Welge-Lüßen, U., Yu, A., Neubauer, A.S., and Kampik, A.
- Published
- 2007
- Full Text
- View/download PDF
21. [The modified treat and extend scheme with injection blocks in intravitreal injection treatment : Retrospective analysis from the routine clinical application].
- Author
-
Take P, Dittmann CA, Mackerodt L, Callizo J, Striebe NA, Hoerauf H, Feltgen N, and Bemme S
- Subjects
- Angiogenesis Inhibitors therapeutic use, Follow-Up Studies, Humans, Intravitreal Injections, Retrospective Studies, Tomography, Optical Coherence, Treatment Outcome, Diabetic Retinopathy drug therapy, Macular Edema drug therapy, Retinal Vein Occlusion drug therapy
- Abstract
Background: Regular treatment with intravitreal operative medication injections (IVOM) and the associated frequent check-ups are a major challenge for many patients, which can lead to treatment discontinuation. The aim of the modified treat and extend (TAE) in blocks scheme is to achieve stable retinal and visual outcomes with as few control visits as possible and thus to minimize the burden for the individual patient., Methods: This monocentric retrospective study examined the treatment courses of 387 patients with neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, who were treated by three blocks of intravitreal injections in the TAE regimen. The primary endpoint was achieving an injection interval of 12 weeks., Results: Intravitreal injections in TAE blocks significantly reduced retinal thickness and improved visual acuity. On average, a treatment interval of 2 months was achieved across the various indications., Conclusion: Intravitreal injections in TAE blocks of three injections can reduce patients' burden and lead to stable retinal and visual results.
- Published
- 2021
- Full Text
- View/download PDF
22. Intravitreales Bevacizumab bei chronischer Retinopathia centralis serosa.
- Author
-
Niegel, M.F., Schrage, N.F., Christmann, S., and Degenring, R.F.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2008
- Full Text
- View/download PDF
23. Bessere Aussichten bei altersbedingter Makuladegeneration: Neue therapeutische Möglichkeiten
- Author
-
Kernt, Marcus, Wolf, Armin, and Kampik, Anselm
- Published
- 2013
- Full Text
- View/download PDF
24. [Diagnostic criteria: OCT angiography for retinal angiomatous proliferation (RAP lesions, type 3 neovascularization)].
- Author
-
Valler D, Feucht N, Lohmann CP, Ulbig M, and Maier M
- Subjects
- Cell Proliferation, Fluorescein Angiography, Humans, Indocyanine Green, Macular Degeneration, Tomography, Optical Coherence, Choroidal Neovascularization, Retinal Neovascularization
- Abstract
Background: Multimodal imaging of retinal angiomatous proliferation (RAP) lesions (type 3 neovascularization) and the diagnostic significance of optical coherence tomography angiography (OCT-A)., Material and Methods: Confirmation of the diagnosis in six case reports with fundus photography, optical coherence tomography (OCT), fluorescein angiography (FLA), indocyanine green angiography (ICGA) and optical coherence tomography angiography (OCT‑A)., Results and Conclusion: The use of OCT‑A is helpful for the diagnosis and follow-up examinations of RAP lesions (type 3 neovascularization). It enables the detailed visualization of intraretinal and choroidal microcirculation. Furthermore, it is possible to evaluate the progression, classify the stages and comprehend the treatment strategy.
- Published
- 2020
- Full Text
- View/download PDF
25. [Trabeculectomy with Ologen® implant and bevacizumab].
- Author
-
Glandorf K, Lommatzsch C, Heinz C, and Koch JM
- Subjects
- Bevacizumab, Collagen, Glycosaminoglycans, Humans, Intraocular Pressure, Mitomycin, Retrospective Studies, Treatment Outcome, Trabeculectomy
- Abstract
Background: Trabeculectomy is the most frequent form of glaucoma surgery. Despite the intraoperative use of antimetabolites, such as mitomycin C (MMC) postoperative scarring reactions can cause surgical failure. The subconjunctival placement of an Ologen® implant can avoid wound scarring. The additional application of bevacizumab should reduce angiogenesis and thereby scarring reactions and improve the surgical success rate., Methods: This was a retrospective single center study of patients with glaucoma after trabeculectomy with MMC. The operation was carried out either without an Ologen® implant (group 1), or with an Ologen® implant as an bevacizumab depot (group 2) or with an Ologen® implant and intrachamber injection of bevacizumab (group 3). The follow-up postoperative observation of intraocular pressure (IOP), complications, subsequent interventions and antiglaucoma treatment was performed for 12 months., Results: There were no significant differences between the groups with respect to IOP, complications, subsequent interventions and postoperative antiglaucoma treatment. The highest success rate (IOP after 12 months ≤15 mm Hg without treatment) was in group 1 (77.5%), followed by group 2 with 63.6% and group 3 with 57.1% (p = 0.34, χ
2 -test)., Conclusion: The highest success rate was achieved in group 1 with MMC but without an Ologen® implant or bevacizumab. In this study the additional use of Ologen® implants and bevacizumab in trabeculectomy was found to be a safe operation method but did not provide any additional benefits.- Published
- 2020
- Full Text
- View/download PDF
26. [Central venous occlusion in Wyburn-Mason syndrome].
- Author
-
Toepffer AM, Wecke T, Hoffmann MB, and Thieme H
- Subjects
- Angiogenesis Inhibitors, Fluorescein Angiography, Humans, Intravitreal Injections, Macular Edema, Ranibizumab, Tomography, Optical Coherence, Visual Acuity, Retinal Vein Occlusion
- Abstract
The diagnostic findings, therapy and course of disease are described for a case of central venous occlusion in Wyburn-Mason-Syndrome. The diagnosis was based on OCT, fluorescein angiography and cMRI. In addition, due to the macular edema an intravitreal injection with Ranibizumab was applied. The macular edema regressed and further Ranibizumab-injections as well as a panretinal laser-coagulation and possibly a cryocoagulation were planned. For a central venous occlusion with macular edema also in Wyburn-Mason-Syndrome an intravitreal anti-VEGF-inhibition leads to an improvement.
- Published
- 2020
- Full Text
- View/download PDF
27. Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe
- Author
-
Vécsei-Marlovits, P. V., Binder, S., and Stur, M.
- Published
- 2009
- Full Text
- View/download PDF
28. Intravitreale Pharmakotherapie retinaler Erkrankungen und Komplikationen intravitrealer Injektionen
- Author
-
Egger, S. F., Ortner, C., Nischler, C., Hufnagel, C., Spaun, J., and Grabner, G.
- Published
- 2007
- Full Text
- View/download PDF
29. [Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema : 1‑year results of the German POLARIS cohort].
- Author
-
Ulbig M, Höh H, Schmickler S, Wolf A, Dimopoulos S, Lorenz K, Bauer-Steinhusen U, and Wiedemann P
- Subjects
- Angiogenesis Inhibitors, Germany, Humans, Intravitreal Injections, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A, Diabetic Retinopathy drug therapy, Macular Edema, Ranibizumab therapeutic use
- Abstract
Background: Currently only few data are available on the treatment reality with ranibizumab in patients with diabetic macular edema (DME)., Material and Methods: POLARIS is an international observational study which included 983 patients who were treated with ranibizumab due to DME. The primary objective of the study was to investigate the influence of treatment and control intervals as well as resource utilization on the mean change in visual acuity. Secondary endpoints included the collation of disease activity monitoring in the clinical practice. This article describes the results of the German POLARIS population. The study was conducted in 8 European countries from October 2012 to January 2015., Results: In Germany 220 patients were included in the study. Visual acuity improved by 4.3 letters within the first 3 months of treatment. At 12 months, visual acuity increased on average by 4.1 (SD ± 12.4) letters (approximately 1 line) for 168 patients enrolled in the efficacy analysis. Patients received an average of 4.5 (SD ± 1.9) injections, 10.3 (SD ± 6.3) visual acuity tests and 3.3 (SD ± 3.1) optical coherence tomography (OCT) examinations during the first year. Patients with ≤3 injections showed an average improvement in visual acuity by 2.7 letters which was less improvement compared to patients with >3 injections, who achieved an average improvement of 5.4 letters. There was a correlation between the number of injections and the visual acuity achieved., Discussion: For Germany, the results of the POLARIS study indicate that despite a high number of visits, patients with DME are undertreated in clinical routine practice. The injection frequency in Germany was lower than in randomized clinical trials. Almost half of the patients received less than 4 injections in the first year of treatment and thus showed an undertreatment compared to the recommendations of German and international medical societies.
- Published
- 2019
- Full Text
- View/download PDF
30. [Importance of vitrectomy in endophthalmitis : How immediate vitrectomy can restore visual acuity].
- Author
-
Damm LJ, Boden KT, and Januschowski K
- Subjects
- Antibodies, Monoclonal, Humanized, Bevacizumab, Humans, Intravitreal Injections, Retrospective Studies, Vascular Endothelial Growth Factor A, Visual Acuity, Vitrectomy, Endophthalmitis surgery, Macular Degeneration
- Abstract
This article presents a case of endophthalmitis after intravitreal injection with bevacizumab (Avastin®) in a patient suffering from exudative age-related macular degeneration (AMD). Within 1h after diagnosis the patient underwent vitrectomy with intravitreal injection of antibiotics combined with corticosteroids and 4 weeks after the endophthalmitis the visual acuity increased to 0.5. This case report demonstrates that an immediate vitrectomy combining intravitreal injection of medication can lead to a good visual outcome even in the case of severe endophthalmitis.
- Published
- 2019
- Full Text
- View/download PDF
31. [Reasons for delayed and discontinued therapy in age-related macular degeneration].
- Author
-
Wintergerst MWM, Bouws J, Loss J, Heimes B, Pauleikhoff D, Holz FG, and Finger RP
- Subjects
- Age Distribution, Angiogenesis Inhibitors, Humans, Intravitreal Injections, Surveys and Questionnaires, Macular Degeneration
- Abstract
Background: Critical prerequisites for successful therapy of neovascular age-related macular degeneration (nvAMD) are an early initiation and continuous monitoring; however, delays in starting therapy and non-medically indicated discontinuation of therapy are frequent, which limits therapy efficacy and, thus, visual outcomes., Objective: To identify the reasons for delay in therapy and non-medically indicated termination of therapy., Material and Methods: Patients who had started a new therapy (starters) and those who independently terminated therapy (dropouts) were interviewed by telephone with a specific, standardized questionnaire. Results were summarized descriptively., Results: A total of 100 starters and 55 dropouts were interviewed. The mean therapy delay was 22 (±28 SD) days. This was mainly due to the time until the decision to see an ophthalmologist was made. Main reasons for dropping out were: transportation issues (27%), poor general health (25%) and the assumption that there is no benefit from therapy (11%). Of the patients who dropped out 63% would have liked to continue therapy., Conclusion: There is potential for improvement in nvAMD management regarding therapy start as well as therapy maintenance. Sensitizing for initial nvAMD symptoms is important as is reduction of barriers to therapy maintenance, since most therapy dropouts would like to continue the therapy.
- Published
- 2018
- Full Text
- View/download PDF
32. Cloning and expression of the anti-VEGF-molecule RA-01 in vitro
- Author
-
Wagner Lima, Nina and Klinik und Poliklinik für Augenheilkunde JLU
- Subjects
genetic structures ,Makuladegeneration ,anti-VEGF ,Ranibizumab ,Maculadegenaration ,ddc:610 ,Medical sciences Medicine - Abstract
Neovaskuläre Erkrankungen der Netzhaut, wie die altersabhängige Makuladegeneration oder die diabetische Retinopathie, nehmen in der zunehmend älter werdenden Bevölkerung rapide zu. Grundlage der neovaskulären Erkrankungen ist ein überschießen¬des Blutgefäßwachstum in die Retina ausgelöst durch eine gesteigerte Aktivität des vascular endothelial growth factor (VEGF). Die aktuelle Therapiemethode besteht in der monatlich zu wiederholenden intravitrealen Injektion von anti-VEGF Molekülen wie Bevacizumab oder Ranibizumab. Der Nachteil dieser Behandlung ist jedoch der invasive Charakter der intravitrealen Injektion sowie die hohe finanzielle Belastung für die Patienten und das Gesundheitssystem. Ziel dieser Arbeit ist die Entwicklung eines Expressionssystems, mit dem das anti-VEGF F(ab)-Molekül Ranibizumab (RA-01) in eukaryotischen Zellen produziert werden kann. Die DNA Sequenz beider Peptide des F(ab) Fragmentes wurden für eine Expression in eukaryotischen Zellen durch Basenmodifizierung, Anhängen einer sekretorischen Leadersequenz und der Generierung bestimmter Enzymschnittstellen optimiert. Zwischen die DNA Sequenzen wurde eine internal ribosomal entry site (IRES) kloniert, um eine gleichzeitig Expression beider Peptide zu gewährleisten. Die Plasmide wurden in HEK293, HELA und arpe19 Zellkulturen transfiziert und das exprimierte Protein im Überstand per Western blot detektiert. Ein Ranibizumab spezifischer ELISA wurde entwickelt, um die Konzentration von RA-01 im Überstand messen zu können. Die biologische Aktivität von RA-01 wurde in einem human umbilical vein endothelial cell (HUVEC) planar migration assay nachgewiesen. RA-01 konnte im Überstand von allen getesteten Zellkulturen nach Transfizierung detektiert werden. Aufgrund der höchsten Transfektionsrate wurden für die Produktion des Proteins für weitere biologische Messungen HEK293 Zellen transfiziert. Die Konzentration des Proteins konnte per ELISA gemessen werden (0,378µg/ml). Eine Konzentration von 37,8ng RA-01 konnte im HUVEC Migrationsassay die VEGF induzierte Migration um 50% hem¬men, ähnlich der Hemmungsaktivität von 100ng kommerziell erhältlichem Ranibizumab (Lucentis®). In dieser Arbeit wurde somit erfolgreich ein biologisch aktives anti-VEGF F(ab) Fragment in eukaryotischen Zellen in vitro hergestellt. Die Aktivität von RA-01 ist mindestens so hoch wie rekombinant in Bakterien hergestelltes, kommerziell erhältliches Ranibizumab. Somit kann zukünftig unter Nutzung vorhandener Transfer- und Regulationssysteme RA-01 in vivo in der Retina hergestellt werden. Diese neue Behandlungsmethode könnte zukünftig die regelmäßige intraokuläre Injektion von anti-VEGF Molekülen ersetzen und einen kosten-günstigeren und weniger invasiven Therapie der neovaskulären Erkrankungen der Netzhaut darstellen. Neovascular diseases of the retina, like the age-related macular degeneration or diabetic retinopathy, play an increasingly important role in the aging population. The pathogenetic mechanism of such neovascular diseases is an excessive and uncontrolled growth of blood vessels in the retina caused by the increased activity of vascular endothelial growth factor (VEGF). The current therapy of choice consists of monthly intraocular injections of anti-VEGF molecules, such as Bevacizumab or Ranibizumab. The disadvantage of this treatment is the invasive character of the intravitreal injection and the high financial burden for the patient and the healthcare system. The purpose of this study is to develop an expression system in order to produce the anti-VEGF F(ab) molecule Ranibizumab (RA-01) in eukaryotic cells. The DNA sequence of both peptides of the F(ab) fragment were optimized for expression in eukaryotic cells by modifying the base composition, adding a secretory leader sequence, and generating certain enzyme cleavage sites. An internal ribosomal entry site (IRES) was cloned between the DNA sequences in order to ensure a simultaneous expression of both peptides. The plasmids were transfected into HEK 293, HeLa and arpe 19 cell cultures and the target protein was detected in the supernatant by Western blot. A Ranibizumab specific ELISA was developed to measure the concentration of RA-01. The biological activity of RA-01 was detected in a human umbilical vein endothelial cell (HUVEC) planar migration assay. After transfection, RA-01 was detected in the supernatant of all tested cell cultures. Due to the highest transfection rate, HEK 293 cells were used for further biological measurements. The protein concentration could successfully be measured by ELISA (0.378 µg/ml). A concentration of 37.8 ng RA-01 was sufficient to inhibit the VEGF-induced migration by 50% in the HUVEC migration assay, similar to the inhibitory activity of 100 ng of commercially available Ranibizumab (Lucentis®). This work demonstrates the successful expression of a biologically active anti-VEGF F(ab) fragment in eukaryotic cells in vitro. The activity of RA-01 is at least as high as commercially available Ranibizumab recombinantly produced in bacterial cells. In the future, RA-01 may be manufactured in vivo in the retina using existing transfer and regulatory systems. This new treatment could replace the regular intraocular injection of anti-VEGF molecules and would be a cheaper and less invasive treatment of neovascular diseases of the retina.
- Published
- 2012
33. Klonierung und Expression des anti-VEGF-Moleküls RA-01 in vitro
- Author
-
Wagner Lima, Nina and Justus Liebig University Giessen
- Subjects
ddc:610 ,Makuladegeneration ,anti-VEGF ,Ranibizumab ,Maculadegenaration - Abstract
Neovaskuläre Erkrankungen der Netzhaut, wie die altersabhängige Makuladegeneration oder die diabetische Retinopathie, nehmen in der zunehmend älter werdenden Bevölkerung rapide zu. Grundlage der neovaskulären Erkrankungen ist ein überschießen¬des Blutgefäßwachstum in die Retina ausgelöst durch eine gesteigerte Aktivität des vascular endothelial growth factor (VEGF). Die aktuelle Therapiemethode besteht in der monatlich zu wiederholenden intravitrealen Injektion von anti-VEGF Molekülen wie Bevacizumab oder Ranibizumab. Der Nachteil dieser Behandlung ist jedoch der invasive Charakter der intravitrealen Injektion sowie die hohe finanzielle Belastung für die Patienten und das Gesundheitssystem. Ziel dieser Arbeit ist die Entwicklung eines Expressionssystems, mit dem das anti-VEGF F(ab)-Molekül Ranibizumab (RA-01) in eukaryotischen Zellen produziert werden kann.Die DNA Sequenz beider Peptide des F(ab) Fragmentes wurden für eine Expression in eukaryotischen Zellen durch Basenmodifizierung, Anhängen einer sekretorischen Leadersequenz und der Generierung bestimmter Enzymschnittstellen optimiert. Zwischen die DNA Sequenzen wurde eine internal ribosomal entry site (IRES) kloniert, um eine gleichzeitig Expression beider Peptide zu gewährleisten. Die Plasmide wurden in HEK293, HELA und arpe19 Zellkulturen transfiziert und das exprimierte Protein im Überstand per Western blot detektiert. Ein Ranibizumab spezifischer ELISA wurde entwickelt, um die Konzentration von RA-01 im Überstand messen zu können. Die biologische Aktivität von RA-01 wurde in einem human umbilical vein endothelial cell (HUVEC) planar migration assay nachgewiesen.RA-01 konnte im Überstand von allen getesteten Zellkulturen nach Transfizierung detektiert werden. Aufgrund der höchsten Transfektionsrate wurden für die Produktion des Proteins für weitere biologische Messungen HEK293 Zellen transfiziert. Die Konzentration des Proteins konnte per ELISA gemessen werden (0,378µg/ml). Eine Konzentration von 37,8ng RA-01 konnte im HUVEC Migrationsassay die VEGF induzierte Migration um 50% hem¬men, ähnlich der Hemmungsaktivität von 100ng kommerziell erhältlichem Ranibizumab (Lucentis®).In dieser Arbeit wurde somit erfolgreich ein biologisch aktives anti-VEGF F(ab) Fragment in eukaryotischen Zellen in vitro hergestellt. Die Aktivität von RA-01 ist mindestens so hoch wie rekombinant in Bakterien hergestelltes, kommerziell erhältliches Ranibizumab. Somit kann zukünftig unter Nutzung vorhandener Transfer- und Regulationssysteme RA-01 in vivo in der Retina hergestellt werden. Diese neue Behandlungsmethode könnte zukünftig die regelmäßige intraokuläre Injektion von anti-VEGF Molekülen ersetzen und einen kosten-günstigeren und weniger invasiven Therapie der neovaskulären Erkrankungen der Netzhaut darstellen., Neovascular diseases of the retina, like the age-related macular degeneration or diabetic retinopathy, play an increasingly important role in the aging population. The pathogenetic mechanism of such neovascular diseases is an excessive and uncontrolled growth of blood vessels in the retina caused by the increased activity of vascular endothelial growth factor (VEGF). The current therapy of choice consists of monthly intraocular injections of anti-VEGF molecules, such as Bevacizumab or Ranibizumab. The disadvantage of this treatment is the invasive character of the intravitreal injection and the high financial burden for the patient and the healthcare system. The purpose of this study is to develop an expression system in order to produce the anti-VEGF F(ab) molecule Ranibizumab (RA-01) in eukaryotic cells.The DNA sequence of both peptides of the F(ab) fragment were optimized for expression in eukaryotic cells by modifying the base composition, adding a secretory leader sequence, and generating certain enzyme cleavage sites. An internal ribosomal entry site (IRES) was cloned between the DNA sequences in order to ensure a simultaneous expression of both peptides. The plasmids were transfected into HEK 293, HeLa and arpe 19 cell cultures and the target protein was detected in the supernatant by Western blot. A Ranibizumab specific ELISA was developed to measure the concentration of RA-01. The biological activity of RA-01 was detected in a human umbilical vein endothelial cell (HUVEC) planar migration assay. After transfection, RA-01 was detected in the supernatant of all tested cell cultures. Due to the highest transfection rate, HEK 293 cells were used for further biological measurements. The protein concentration could successfully be measured by ELISA (0.378 µg/ml). A concentration of 37.8 ng RA-01 was sufficient to inhibit the VEGF-induced migration by 50% in the HUVEC migration assay, similar to the inhibitory activity of 100 ng of commercially available Ranibizumab (Lucentis®). This work demonstrates the successful expression of a biologically active anti-VEGF F(ab) fragment in eukaryotic cells in vitro. The activity of RA-01 is at least as high as commercially available Ranibizumab recombinantly produced in bacterial cells. In the future, RA-01 may be manufactured in vivo in the retina using existing transfer and regulatory systems. This new treatment could replace the regular intraocular injection of anti-VEGF molecules and would be a cheaper and less invasive treatment of neovascular diseases of the retina.
- Published
- 2012
- Full Text
- View/download PDF
34. [Volumetric analysis of vascularized pigment epithelium detachment in AMD: post hoc analysis of the RECOVER study].
- Author
-
Clemens CR, Alten F, Heiduschka P, Gamulescu MA, Wolf A, and Eter N
- Subjects
- Fluorescein Angiography, Humans, Indocyanine Green, Retinal Pigment Epithelium, Retrospective Studies, Tomography, Optical Coherence, Choroidal Neovascularization, Macular Degeneration, Retinal Detachment
- Abstract
Background: The ratio of choroidal neovascularization (CNV) and pigment epithelium detachment (PED) represents an important parameter regarding the risk of developing a tear of the retinal pigment epithelium (RPE) in patients with vascularized PED due to age-related macular degeneration (AMD)., Methods: Within the framework of the RECOVER study a total of 29 treatment-naive patients with vascularized PED underwent fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) volume scans. The CNV-PED ratio was evaluated retrospectively by two independent graders in three ways: 1) manually based on the en face image of the FA late phase and 2) manually based on the en face image of the ICGA late phase. 3) In every OCT scan encompassing the PED, the area between the RPE and Bruch's membrane and the CNV area was measured and multiplied by the distance between OCT scans in order to determine volumetric data of CNV, PED and the serous cavity., Results: The FA and ICGA showed a mean serous area of 6.14 ± 4.21 mm
2 (ICGA 5.94 ± 4.13 mm2 ), a mean CNV area of 3.25 ± 1.79 mm2 (ICGA 2.84 ± 1.68 mm2 ) and a mean PED area of 9.39 ± 4.27 mm2 (ICGA 8.79 ± 4.23 mm2 ) resulting in a mean two-dimensional morphological ratio of 0.35 ± 0.21 (ICGA 0.32 ± 0.22). The volumetric measurement revealed a mean CNV volume of 0.63 ± 0.67 mm3 , a mean serous volume of 3.61 ± 3.83 mm3 and a mean total PED volume of 4.25 ± 3.68 mm3 . The mean three-dimensional morphological ratio was 0.15 ± 0.29. The difference between the two-dimensional ratios of FA (p < 0.0001) and ICGA (p = 0.0004) was significant compared to the three-dimensional OCT ratio., Conclusion: Assessment of the CNV-PED ratio using volumetric OCT measurements is an additional tool to the en face modalities FA and ICGA. This seems to be clinically relevant regarding the risk stratification of RPE tear development in PED patients and for the planning of the treatment regimen.- Published
- 2018
- Full Text
- View/download PDF
35. [Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].
- Author
-
Walz JM, Bemme S, Reichl S, Akman S, Breuß H, Süsskind D, Glitz B, Müller VC, Wagenfeld L, Gabel-Pfisterer A, Aisenbrey S, Engelmann K, Koutsonas A, Krohne TU, and Stahl A
- Subjects
- Angiogenesis Inhibitors, Germany, Gestational Age, Humans, Infant, Infant, Newborn, Intravitreal Injections, Laser Coagulation, Registries, Retina, Vascular Endothelial Growth Factor A, Retinopathy of Prematurity
- Abstract
Background: Retinopathy of prematurity (ROP) is one of the main reasons for childhood blindness. The number of infants requiring treatment, however, is low for individual centers. The Retina.net ROP registry has been founded to allow a joint analysis of treatment patterns and courses post treatment., Objective: This paper reports treatment patterns over 5 years., Material and Methods: All infants born between January 2011 and December 2015 who were entered into the treatment registry by one of the 12 participating centers were analyzed., Results: The data of 150 infants (292 eyes) were analyzed and ROP 3+ in zone II was the most prevalent treatment indication. Gestational age and birth weight remained stable over the years. The treatment patterns, however, changed with anti-VEGF treatment (bevacizumab or ranibizumab) accounting for only 10% of treated eyes in 2011 but for 56% and 30% in 2014 and 2015, respectively. Almost all eyes with AP-ROP or zone I disease received anti-VEGF treatment. Zone II disease was predominantly treated with laser photocoagulation. Recurrences were more common and appeared later in the anti-VEGF group compared to the laser group (23%/interval 60 days vs. 17%/interval 23 days). Perioperative complications were evenly distributed across treatment groups., Conclusion: The data in this analysis represent about 10-15% of treated infants in Germany. The results provide evidence for an increasing use of anti-VEGF agents for ROP. The data reflect a selection bias for anti-VEGF treatment in eyes with a more aggressive disease. This needs to be considered when interpreting data such as disease recurrence rates. The risk for late recurrences after anti-VEGF treatment is of particular clinical significance.
- Published
- 2018
- Full Text
- View/download PDF
36. [Newly occurring loss of visual acuity in choroidal osteoma].
- Author
-
Schuh A, Foerster P, Priglinger S, and Eibl-Lindner K
- Subjects
- Angiogenesis Inhibitors, Choroid, Fluorescein Angiography, Humans, Intravitreal Injections, Ranibizumab, Visual Acuity, Choroid Neoplasms, Choroidal Neovascularization, Osteoma
- Abstract
Purpose: Approach to loss of visual acuity in a patient with a choroidal osteoma (CO) which had been stable for seven years., Methods: Fluorescence angiography confirmed a choroidal neovascularization (CNV) as the cause of the loss of visual acuity. Treatment with intravitreal (IVT) injection of ranibizumab., Results: Increase of visual acuity and decrease of edema after IVT injection., Conclusion: Monitoring is necessary even for primarily benign CO in order to detect secondary complications causing loss of visual acuity, e. g. secondary CNV. Anti-VEGF IVT represents an approved treatment option.
- Published
- 2018
- Full Text
- View/download PDF
37. [Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].
- Author
-
Heimes B, Schick T, Brinkmann CK, Wiedon A, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, and Schmitz-Valckenberg S
- Subjects
- Blindness epidemiology, Blindness etiology, Diabetic Retinopathy diagnosis, Diabetic Retinopathy drug therapy, Fluorescein Angiography, Germany, Humans, Intravitreal Injections, Macular Degeneration complications, Macular Degeneration diagnosis, Macular Degeneration drug therapy, Macular Edema complications, Macular Edema diagnosis, Macular Edema drug therapy, Quality Assurance, Health Care, Retina drug effects, Retinal Vein Occlusion complications, Retinal Vein Occlusion diagnosis, Retinal Vein Occlusion drug therapy, Surveys and Questionnaires, Treatment Outcome, Blindness diagnosis, Blindness drug therapy, Ranibizumab therapeutic use, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Background: The prevalence of blindness as defined by law could be reduced by the introduction of anti-vascular endothelial growth factor (VEGF) therapy. Because the treatment is governed by patient needs, mostly using morphological criteria, imaging diagnostics are of particular importance. The non-interventional OCEAN study investigates the treatment with ranibizumab in the clinical routine practice. In a subgroup of patients the interpretation of spectral domain optical coherence tomography (SD-OCT) scans by the treating physicians will be analyzed (ORCA module)., Methods: Over a period of 24 months data from patients with exudative age-related macular degeneration (AMD), macular edema due to retinal vein occlusion or diabetes mellitus, who are receiving intravitreal injections of ranibizumab, will be assessed. Information on examinations, visual acuity, treatment and recordings from imaging techniques will be documented using a questionnaire. The SD-OCT scans, fluorescence angiography and fundus photography will be independently analyzed by the ophthalmologist of the study center and by three reading centers (CIRCL Cologne, GRADE Bonn and M3 Münster). Automated measurements of retinal thickness by the manufacturers' software will be checked and if necessary manually corrected. A qualitative interpretation in terms of morphological criteria for (further) treatment will be performed., Conclusion: A thorough assessment of SD-OCT images during anti-VEGF therapy provides the basis for the best possible needs-oriented treatment regimen. The control of the quality of data from daily routine practice may indicate possible weaknesses allowing explicit training and therefore optimization of patient treatment.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.